Cargando…

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer

OBJECTIVE: Although the utility of immunohistochemistry (IHC) for assessing mismatch repair (MMR) protein expression has been demonstrated in solid tumors including primary prostate cancer (PCa), its utility has not been assessed in castration-resistant PCa (CRPC). METHODS: Tissue microarrays were c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nghiem, Belinda, Zhang, Xiaotun, Lam, Hung-Ming, True, Lawrence D., Coleman, Ilsa, Higano, Celestia S., Nelson, Peter S., Pritchard, Colin C., Morrissey, Colm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730872/ https://www.ncbi.nlm.nih.gov/pubmed/29264190 http://dx.doi.org/10.1016/j.ajur.2016.09.002

Ejemplares similares

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
por: Nguyen, Holly M., et al.
Publicado: (2017)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer
por: Kumar, Akash, et al.
Publicado: (2016)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes
por: Gordon, Ryan R., et al.
Publicado: (2014)

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
por: Schweizer, Michael T., et al.
Publicado: (2016)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
por: Pritchard, Colin C., et al.
Publicado: (2014)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
por: Brady, Lauren, et al.
Publicado: (2021)

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
por: Ruppender, Nazanin, et al.
Publicado: (2015)

Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
por: Patel, Radhika A., et al.
Publicado: (2022)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Genetic background influences murine prostate gene expression: implications for cancer phenotypes
por: Bianchi-Frias, Daniella, et al.
Publicado: (2007)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature
por: Labrecque, Mark P., et al.
Publicado: (2021)

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer
por: De Sarkar, Navonil, et al.
Publicado: (2021)

Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial
por: Finelli, Antonio, et al.
Publicado: (2021)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways
por: Chéry, Lisly, et al.
Publicado: (2014)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach
por: Bossio, Jennifer A., et al.
Publicado: (2021)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford
por: Abrha, Aser, et al.
Publicado: (2020)

Single cell transcriptomic analysis of prostate cancer cells
por: Welty, Christopher J, et al.
Publicado: (2013)

Assessing the nutritional needs of men with prostate cancer
por: McLaughlin, Kaitlin, et al.
Publicado: (2019)

Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors
por: Cherrier, Monique M., et al.
Publicado: (2021)

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
por: George, Daniel J., et al.
Publicado: (2022)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2023)

Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate
por: Pascal, Laura E, et al.
Publicado: (2008)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_epp4d9a1a8huun1at1v750n7u5